Gomak Inc. Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics

• Revenue: 120M EUR (FY 2022).
• EBITDA Margin: 14.5% (down from 18% in 2020).
• R&D Spend: 8% of revenue, primarily focused on legacy product maintenance.
• Debt/Equity Ratio: 1.2x, limiting new financing capacity without equity dilution.

Operational Facts

• Manufacturing: Three plants located in France, Poland, and Brazil.
• Capacity Utilization: 65% in France, 85% in Poland, 40% in Brazil.
• Headcount: 1,400 employees; 60% of workforce is unionized in the French facility.
• Product Lifecycle: Core product line is in the maturity phase; new product pipeline is stalled for 18 months.

Stakeholder Positions

• CEO (Jean-Luc Moreau): Prioritizes short-term margin recovery to meet investor expectations.
• CTO (Elena Rossi): Advocates for a 25M EUR investment in digital transformation to enable long-term competitiveness.
• Union Representative (Marc Dubois): Opposes any headcount reduction in French facilities.

Information Gaps

• Market share data for the Brazilian segment is missing.
• Specific cost-per-unit breakdown between the French and Polish plants is not provided.
• Customer churn rate for the core product line is estimated rather than sourced.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question

How should Gomak reallocate capital to restore margins while funding the innovation required to avoid product obsolescence?

Structural Analysis

• Value Chain: The current model is cost-heavy in high-wage regions with underutilized capacity. Innovation is trapped by legacy maintenance costs.
• Ansoff Matrix: The company is over-reliant on existing products in existing markets. Market penetration is capped; product development is the only path to growth.

Strategic Options

• Option 1: Aggressive Consolidation. Close the French facility and shift production to Poland. Trade-offs: High severance costs and union strikes; immediate margin expansion.
• Option 2: Targeted Divestiture. Sell the Brazilian unit to raise 30M EUR. Trade-offs: Loss of regional footprint; frees capital for R&D without debt.
• Option 3: Phased Digital Pivot. Maintain current footprint but freeze hiring to fund R&D. Trade-offs: Slow transition; risks being overtaken by competitors before the new product arrives.

Preliminary Recommendation

Pursue Option 2. Divesting the Brazilian unit provides the necessary liquidity to fund the R&D pipeline without triggering the social friction of French plant closures. It allows Gomak to focus on its most efficient manufacturing hubs.

3. Implementation Roadmap (Implementation Specialist)

Critical Path

1. Month 1-2: Engage investment bank for a divestiture valuation of the Brazilian unit.
2. Month 3-4: Negotiate transition service agreements with the buyer.
3. Month 5-6: Reallocate capital to the R&D team and initiate the new product development cycle.

Key Constraints

• Divestiture Speed: Legal requirements in Brazil regarding workforce notification.
• R&D Talent: Current internal team lacks specific digital skills; recruitment is required.

Risk-Adjusted Implementation

If the Brazilian divestiture takes longer than six months, Gomak must implement a temporary 10% reduction in R&D maintenance spend to prevent a cash flow crisis. The plan assumes a 15% margin of error on divestiture proceeds.

4. Executive Review and BLUF (Executive Critic)

BLUF

Gomak faces a binary choice: fix the cost base or fund the future. Divesting the Brazilian unit, as recommended, is the correct move to unlock liquidity, but it ignores the core issue of manufacturing inefficiency in France. The company currently carries too much overhead to support an R&D-heavy future. If the board does not address the French labor cost structure, the R&D investment will simply be consumed by operational losses. The plan is technically sound but lacks the necessary urgency regarding the French facility. Proceed with the divestiture, but mandate a parallel plan for French operational restructuring.

Dangerous Assumption

The assumption that R&D investment alone will restore competitiveness. Without a fundamental change in the French manufacturing cost structure, the firm remains a high-cost producer regardless of its product portfolio.

Unaddressed Risks

• Execution Risk: The team has no experience in managing a divestiture of this size, which may lead to significant value leakage.
• Market Risk: Competitors may lower prices during the transition phase, further eroding the 14.5% margin before the new product reaches the market.

Unconsidered Alternative

Joint Venture in Brazil. Instead of a full sale, enter a JV to retain upside while offloading the operational burden and capital expenditure requirements.

Verdict

APPROVED FOR LEADERSHIP REVIEW (with the caveat that the French restructuring must be addressed in the next planning cycle).